

ASTRAZENECA PLC  
Form 6-K  
March 06, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of March 2019

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82- \_\_\_\_\_

AstraZeneca PLC

INDEX TO EXHIBITS

1.  
Filing of Form 20-F with SEC

6 March 2019 07:00 GMT

FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE COMMISSION

AstraZeneca PLC (the Company) announced today that, on 5 March 2019, it filed its 2018 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at [www.sec.gov](http://www.sec.gov) and also on the Company's website at [www.astrazeneca.com](http://www.astrazeneca.com). The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit [astrazeneca.com](http://astrazeneca.com) and follow us on Twitter @AstraZeneca.

Media Relations

|                                |           |                  |
|--------------------------------|-----------|------------------|
| Gonzalo Viña                   | UK/Global | +44 203 749 5916 |
| Rob Skelding                   | UK/Global | +44 203 749 5821 |
| Matt Kent                      | UK/Global | +44 203 749 5906 |
| Jennifer Hursit                | UK/Global | +44 203 749 5762 |
| Christina Malmberg Hägerstrand | Sweden    | +46 8 552 53 106 |
| Michele Meixell                | US        | +1 302 885 2677  |

Investor Relations

|                     |          |                  |
|---------------------|----------|------------------|
| Thomas Kudsk Larsen |          | +44 203 749 5712 |
| Henry Wheeler       | Oncology | +44 203 749 5797 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

|                    |  |                  |
|--------------------|--|------------------|
| Christer Gruvris   | BioPharma - Cardiovascular; Metabolism | +44 203 749 5711 |
| Nick Stone         | BioPharma - Respiratory; Renal         | +44 203 749 5716 |
| Josie Afolabi      | Other                                  | +44 203 749 5631 |
| Craig Marks        | Finance; Fixed Income                  | +44 7881 615 764 |
| Jennifer Kretzmann | Retail Investors; Corporate Access     | +44 203 749 5824 |
| US toll-free       |  | +1 866 381 72 77 |

Adrian Kemp  
Company Secretary  
AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 06 March 2019

By: /s/ Adrian Kemp

Name: Adrian Kemp

Title: Company Secretary